High Risk · 37/100Jul 14, 4:16 PM EDT
Crescent Biopharma Launches Public Offering of Shares and Warrants
CBIO
Crescent Biopharma (CBIO) has initiated an underwritten public offering of ordinary shares and pre-funded warrants, with underwriters receiving a 30-day option to buy up to 15% additional shares. This dilutive event may pressure the stock price in the near ter…
- ▹Dilutive offering signals cash need and potential runway risk
- ▹Single-asset micro-cap with no clear regulatory or commercial catalysts